Advertisement

Topics

BiondVax enrols first patient in phase 3 second cohort of M-001 flu vaccine

05:24 EDT 8 Jul 2019 | Pharmaceutical Business Review

Close to 8,000 participants are being enrolled by BiondVax for the second cohort for the late-stage trial of M-001 in 85 sites across seven countries in eastern Europe.

The post BiondVax enrols first patient in phase 3 second cohort of M-001 flu vaccine appeared first on Pharmaceutical Business review.

Original Article: BiondVax enrols first patient in phase 3 second cohort of M-001 flu vaccine

NEXT ARTICLE

More From BioPortfolio on "BiondVax enrols first patient in phase 3 second cohort of M-001 flu vaccine"

Advertisement
Quick Search
Advertisement
Advertisement